IL17A and psoriasis: Secukinumab(SEC; AIN457; Cosentyx) is a fully human IgG1κ mAb that specifically targets IL-17A, which has been approved for the treatment of PsA, AS, psoriasis, moderate to severe plaque psoriasis (PSO), and axSpA (213).